Skip to content
DataLookout
Menu

NCT06643728

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 27 words
    • Trial completed
    • Study completion date changed from estimate of Jan 2027 to Oct 27, 2026
    • Site details revised at 1 of 12 sites
  2. Minor Enrollment target: estimated 240 to confirmed 252
    • Primary completion date changed from estimate of Apr 2026 to Jan 16, 2026
    v11
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 12 of 12 sites
    v10
  4. Minor Site contacts updated at 7 of 12 sitesv9
  5. Minor Site contacts updated at 7 of 12 sitesv8
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Site details revised at 12 of 12 sitesv7
  2. Notable Enrollment target: 140 to 240v6 Show 6 more changesShow less
    • Study sites: 10 to 12
    • Primary completion date: Feb 2026 to Apr 2026
    • Study completion date: Nov 2026 to Jan 2027
    • Interventions: Bimagrumab (Drug), Placebo (Drug), Tirzepatide (Drug) to Bimagrumab (Drug), Bimagrumab Placebo (Drug), Tirzepatide (Drug), Tirzepatide Placebo (Drug)
    • Secondary endpoints: details revised at 10 of 10 entries
    • Study arms: 7 to 12
  3. Minor Primary completion date: Oct 2025 to Feb 2026
    • Study completion date: Apr 2026 to Nov 2026
    • Site contacts updated at 9 of 10 sites
    v4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 10
    • Start date changed from estimate of Oct 2024 to Oct 21, 2024
    v3
  5. Study Status, Referencesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percent Change from Baseline in Body Weight
Timeframe: Baseline, Week 24

Secondary (10)

Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA)
Change from Baseline in Body Weight
Percentage of Participants Achieving ≥5% Body Weight Reduction
Percentage of Participants Achieving ≥10% Body Weight Reduction
Percentage of Participants Achieving ≥15% Body Weight Reduction
Show 5 moreShow less
Change from Baseline in Waist Circumference
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in Waist-to-Height Ratio (WHtR)
Percent Change from Baseline in Visceral Adipose Tissue (VAT)
Percent Change from Baseline in Total Body Lean Mass by DXA

Arms and interventions

Part A: Bimagrumab Dose 2 + Tirzepatide PlaceboExperimental

Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC

Part A: Bimagrumab Placebo + Tirzepatide Dose 1Active comparator

Participants will receive bimagrumab placebo SC and tirzepatide SC

Part A: Bimagrumab Placebo + Tirzepatide Dose 2Active comparator

Participants will receive bimagrumab placebo SC and tirzepatide SC

Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1Experimental

Participants will receive bimagrumab SC and tirzepatide SC

Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2Experimental

Participants will receive bimagrumab SC and tirzepatide SC

Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2Experimental

Participants will receive bimagrumab SC and tirzepatide SC

Part A: Bimagrumab Placebo + Tirzepatide PlaceboPlacebo comparator

Participants will receive bimagrumab placebo SC and tirzepatide placebo SC

Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1Experimental

Participants will receive bimagrumab SC and tirzepatide SC

Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1Experimental

Participants will receive bimagrumab SC and tirzepatide SC

Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1Experimental

Participants will receive bimagrumab SC and tirzepatide SC

Part B: Bimagrumab Dose 1 + Tirzepatide PlaceboExperimental

Participants will receive bimagrumab SC and tirzepatide placebo SC

Part B: Bimagrumab Placebo + Tirzepatide PlaceboPlacebo comparator

Participants will receive bimagrumab placebo SC and tirzepatide placebo SC

Drugs: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo

Sites

12 sites in 1 country